NAD+ supplements: separating real benefits from TikTok hype

What did @darya.only.one actually say?

The creator made a specific, pointed warning: NAD+ supplementation may not be safe because cancer cells rely on NAD+ to grow, patients with cancer show elevated NAD+ levels, and no long-term human safety data exists yet. She asked viewers whether their providers had discussed "the cancer risks associated with NAD" before prescribing it. That framing, cancer risks as a known concern worth disclosing, is the core claim worth examining.

She stopped short of saying NAD+ causes cancer outright, and credit where it is due, that restraint matters. She positioned this as a signal worth discussing, not a verdict. Still, asking 253,000 TikTok viewers whether they are scared enough to stop using a supplement is a kind of communication that carries weight regardless of the caveats attached.

Does the science back this up?

Partially, yes, and the biology is real enough to take seriously. NAD+ metabolism is genuinely linked to tumor survival. The concern is not invented. Several peer-reviewed studies show that cancer cells upregulate NAD+ biosynthesis pathways to sustain rapid proliferation. But the jump from "cancer cells use NAD+" to "supplementing NAD+ feeds cancer" is not supported by current human evidence.

A 2023 review by Peclat et al. in Nature Metabolism laid this out clearly: NAD+ precursor supplementation increases systemic NAD+ levels, and in preclinical models, this has promoted tumor growth in some contexts. But the same review noted that NAD+ also supports immune cell function, which can actually suppress tumor development. The net effect in humans is unknown. An earlier study by Nacarelli et al. (2019, Nature Cell Biology) found that NAD+ promoted senescence-associated inflammation, a mechanism that could theoretically accelerate cancer in aged tissue. These are legitimate signals. They are not proof of harm in healthy adults taking NMN or NR.

What did they get right, and what did they get wrong?

Right: NAD+ does play a role in cellular proliferation. Right: elevated NAD+ biosynthesis is observed in multiple cancer types. Right: there is no large long-term randomized controlled trial in humans that has tracked cancer incidence in NAD+ supplement users. Those three statements are accurate.

Where the framing gets slippery is the implicit suggestion that this bidirectional biology constitutes a disclosed cancer risk in the same category as, say, hormone therapy or tobacco. It does not, at least not yet. The creator says providers should be discussing "the cancer risks associated with NAD prior to use," but that phrasing implies established risk where the evidence shows theoretical concern. Oncologists have not reached consensus on this. A 2022 systematic review by Weidele et al. in Redox Biology concluded that NAD+ precursors remain investigational in cancer contexts and that causality in humans is unestablished. Presenting a theoretical mechanism as a clinical risk to disclose is a meaningful overstatement, even a well-intentioned one.

What should you actually know?

If you are healthy and considering NAD+ supplementation for general wellness, the current evidence does not support panicking. But it also does not support assuming this is consequence-free. The honest answer is that the long-term human data is thin for everyone, not just cancer patients.

The more defensible concern is for people who already have a cancer diagnosis or a strong family history of certain cancers. In that population, the preclinical data is worth a real conversation with an oncologist before starting any NAD+ protocol. That is a reasonable, evidence-adjacent position. The creator gestures toward this but applies it to everyone, which muddies the message.

NAD+ precursors like NMN and NR have a reasonable short-term safety profile in clinical trials to date. Dollerup et al. (2018, Nature Communications) found no serious adverse events in a 12-week NR trial. Yoshino et al. (2021, Science) found metabolic benefits from NMN without flagging oncologic signals. Neither trial was powered or designed to detect cancer risk. The absence of a signal is not clearance. But it is also not cause for the alarm the video implies.